Remiges Ventures

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

Phost’in Therapeutics engages in the development of anti-cancer new chemical entities (NCEs). It offers N-glycosylation inhibitors that target abnormal pathogenic glycosylation mechanisms. Phost’in Therapeutics was incorporated in 2014 and is based in Montpellier, France.

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.

KisoJi Biotechnology Inc., a biotechnology company, develop cancer therapeutics through antibodies and stem cells. KisoJi Biotechnology Inc. was formerly known as Actium Research Inc. The company is based in Toronto, Canada.

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.

OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.